

Contents lists available at ScienceDirect

Parkinsonism and Related Disorders

journal homepage: www.elsevier.com/locate/parkreldis

Corrigendum

Corrigendum to “Global long-term study on motor and non-motor symptoms and safety of levodopa-carbidopa intestinal gel in routine care of advanced Parkinson's disease patients; 12-month interim outcomes” [Parkinsonism Relat. Disord. 21(3) (2015) 231–235]



Angelo Antonini ^{a,*}, Ashley Yegin ^b, Cornelia Preda ^b, Lars Bergmann ^b, Werner Poewe ^c,
on behalf of the GLORIA study investigators and coordinators

^a Parkinson and Movement Disorders Unit, IRCCS Hospital San Camillo, Venice, Italy

^b AbbVie, Inc., USA

^c Dept of Neurology, Innsbruck Medical University, Austria

The authors regret that errors have been found in the standard deviations depicted in Fig. 1A. The corrected information is shown below, and the authors would like to apologise for any inconvenience caused.




Fig. 1. Mean change from baseline at D1, M6, and M12 of LCIG treatment via PEG tube in A) hours of “Off” time and “On” time with dyskinesias as measured by UPDRS Part IV; B) UPDRS II and UPDRS III scores. Bars are standard deviation. Asterisks represent statistical significance ($p \leq 0.05$) compared to baseline from paired *t*-test. Unified Parkinson's Disease Rating Scale (UPDRS).

DOI of original article: <http://dx.doi.org/10.1016/j.parkreldis.2014.12.012>.

* Corresponding author.

E-mail address: angelo3000@yahoo.com (A. Antonini).

<http://dx.doi.org/10.1016/j.parkreldis.2016.08.012>

1353-8020/© 2016 AbbVie Inc. employs authors Yegin, Preda, and Bergmann. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).